1. Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?
Claude C. Schulman 
European Urology Supplements 
Volume 8, Issue 12, Pages (December 2009)
DOI: /j.eursup
Copyright © 2009 European Association of Urology Terms and Conditions

2. Fig. 1
Results of a meta-analysis of 10 phase 2 studies on intermittent hormone therapy (IHT) showing the percentage of patients off treatment at 2 yr, overall survival, and the percentage of patients progressing to castration-resistant prostate cancer (CRPC) separately for patients with localised prostate cancer (PCa), patients with a prostate-specific antigen (PSA) relapse after radical prostatectomy (RP) or radiotherapy (RT), and patients with node-positive (N+) or metastatic (M+) PCa [18].
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions

3. Fig. 2
Percentage of patients reporting side effects at least once in the South European Uroncological Group (SEUG) trial [19].
HT=hormone therapy; IHT=intermittent hormone therapy.
European Urology Supplements 2009 8, DOI: ( /j.eursup )
Copyright © 2009 European Association of Urology Terms and Conditions